According to the lawsuit, throughout the Class Period, defendants touted rising utilization “across the installed base,” claimed newer customer cohorts were adopting as fast as or faster than prior cohorts, and represented that RxSight’s field teams effectively trained and supported practices to accelerate growth.
According to the lawsuit, these statements were materially false and misleading. In truth, RxSight’s field organization was inadequately structured and underperforming; newer cohorts needed more support than prior cohorts and were adopting more slowly; and utilization across the installed base was declining. As a result, incremental light delivery device (“LDD”) placements did not translate into expected light adjustable lens (“LAL”) volume, undermining RxSight’s growth model. Unaware of these adverse facts, investors purchased RxSight common stock at artificially inflated prices.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
